S
Siyi Intelligence
Robotic devices for clinical and home rehabilitation
About Siyi Intelligence
Siyi Intelligence, established in 2017 by founder and CEO Gavin Yin, is a high-tech company specializing in medical rehabilitation robots. Based in Shanghai International Medical Park, the company develops and commercializes neurorehabilitation solutions for both clinical settings and home use. The firm's business model centers on creating affordable, intelligent rehabilitation equipment to address the growing demand and shortage of resources in the rehabilitation industry. Its products are sold globally across more than 80 countries, serving over 4,000 hospitals and 60,000 families.
The company's flagship product line is the Syrebo® soft robotic hand rehabilitation glove, which combines flexible robotics and neuroscience to help patients with hand dysfunction recover motor abilities. Other key products include the EasyWalk™ exoskeleton walking suit for lower limb assistance, electroencephalogram (EEG)-based assistive Brain-Computer Interfaces (BCIs), and upper limb rehabilitation robots. These devices are designed for patients recovering from conditions like stroke, brain injury, and cerebral palsy. Siyi Intelligence focuses on a B2B and B2C model, supplying to hospitals, clinics, and directly to individuals for home use.
The company was founded to tackle social issues like the shortage of medical resources and an aging population by making rehabilitation technology more accessible. Siyi Intelligence has achieved significant milestones, including receiving CE/FDA certification for its products, securing over 30 authorized patents, and completing a Series A funding round of nearly $15 million in March 2023. This funding, led by Chengdu Bio-town Equity Investment Fund and Tao Capital, is intended to accelerate the development of integrated neurorehabilitation solutions and a digital rehabilitation service platform. The company actively collaborates with academic and medical institutions like Shanghai Jiao Tong University and The Royal Buckinghamshire Hospital to advance rehabilitation theory and technology.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2023 | $15M | $60M | Chengdu Bio-Town Investment | ↗ |
Growth signals
Latest recorded traffic for Siyi Intelligence is 7.6K monthly website visits, up 5.6% over the last three months. Siyi Intelligence's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- CIChengdu Bio-Town Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Siyi Intelligence on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Siyi Intelligence’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






